Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 19 | 2022 | 205 | 5.040 |
Why?
|
| Obesity | 19 | 2024 | 367 | 3.830 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2023 | 139 | 3.100 |
Why?
|
| Insulin Resistance | 9 | 2022 | 79 | 2.580 |
Why?
|
| Overweight | 3 | 2024 | 87 | 1.450 |
Why?
|
| Mitochondria | 3 | 2020 | 12 | 1.370 |
Why?
|
| Blood Glucose | 5 | 2020 | 107 | 1.350 |
Why?
|
| Football | 6 | 2020 | 24 | 1.340 |
Why?
|
| Exercise Therapy | 5 | 2020 | 14 | 1.220 |
Why?
|
| Humans | 41 | 2024 | 14537 | 1.200 |
Why?
|
| C-Reactive Protein | 5 | 2017 | 96 | 1.080 |
Why?
|
| Inflammation | 5 | 2022 | 104 | 1.030 |
Why?
|
| Interleukin-6 | 5 | 2022 | 51 | 1.020 |
Why?
|
| Muscle, Skeletal | 3 | 2021 | 14 | 1.000 |
Why?
|
| Middle Aged | 14 | 2024 | 3601 | 0.940 |
Why?
|
| Body Weight | 1 | 2024 | 111 | 0.910 |
Why?
|
| Feasibility Studies | 1 | 2024 | 101 | 0.910 |
Why?
|
| Female | 21 | 2024 | 9103 | 0.870 |
Why?
|
| Insulins | 1 | 2022 | 3 | 0.830 |
Why?
|
| Subcutaneous Fat, Abdominal | 3 | 2022 | 7 | 0.800 |
Why?
|
| Phospholipids | 2 | 2021 | 13 | 0.790 |
Why?
|
| Adiposity | 2 | 2022 | 96 | 0.780 |
Why?
|
| Young Adult | 13 | 2024 | 2498 | 0.780 |
Why?
|
| Adult | 15 | 2024 | 5913 | 0.760 |
Why?
|
| Mitochondria, Muscle | 1 | 2021 | 2 | 0.750 |
Why?
|
| Sarcopenia | 1 | 2021 | 7 | 0.750 |
Why?
|
| Resistance Training | 3 | 2022 | 5 | 0.720 |
Why?
|
| Depression | 1 | 2021 | 121 | 0.670 |
Why?
|
| Male | 14 | 2022 | 6754 | 0.650 |
Why?
|
| Adipose Tissue | 6 | 2022 | 52 | 0.650 |
Why?
|
| Sports | 2 | 2020 | 43 | 0.610 |
Why?
|
| HIV Infections | 3 | 2024 | 5097 | 0.590 |
Why?
|
| Leptin | 2 | 2014 | 26 | 0.580 |
Why?
|
| Exercise Test | 2 | 2014 | 13 | 0.570 |
Why?
|
| Insulin | 5 | 2022 | 73 | 0.560 |
Why?
|
| Signal Transduction | 1 | 2016 | 33 | 0.540 |
Why?
|
| Fatty Acids | 4 | 2020 | 12 | 0.520 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 1422 | 0.520 |
Why?
|
| Body Mass Index | 4 | 2022 | 321 | 0.490 |
Why?
|
| Fasting | 2 | 2024 | 16 | 0.480 |
Why?
|
| Glucose Tolerance Test | 3 | 2021 | 33 | 0.470 |
Why?
|
| Subcutaneous Fat | 4 | 2022 | 9 | 0.470 |
Why?
|
| Physical Conditioning, Human | 1 | 2014 | 2 | 0.470 |
Why?
|
| Body Composition | 5 | 2024 | 153 | 0.460 |
Why?
|
| Vitamin D Deficiency | 2 | 2024 | 27 | 0.450 |
Why?
|
| Oxygen Consumption | 4 | 2017 | 15 | 0.400 |
Why?
|
| Metabolic Syndrome | 2 | 2022 | 64 | 0.380 |
Why?
|
| South Africa | 8 | 2024 | 7596 | 0.370 |
Why?
|
| Heart Rate | 3 | 2016 | 32 | 0.370 |
Why?
|
| Cross-Over Studies | 3 | 2016 | 40 | 0.340 |
Why?
|
| Athletic Performance | 2 | 2020 | 6 | 0.330 |
Why?
|
| Australia | 4 | 2022 | 48 | 0.300 |
Why?
|
| Physical Exertion | 3 | 2017 | 3 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 44 | 0.290 |
Why?
|
| Pilot Projects | 2 | 2024 | 179 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 244 | 0.270 |
Why?
|
| Glucose | 2 | 2022 | 45 | 0.260 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 468 | 0.250 |
Why?
|
| Accelerometry | 2 | 2022 | 19 | 0.250 |
Why?
|
| Bicycling | 2 | 2014 | 6 | 0.230 |
Why?
|
| Cholestanes | 1 | 2024 | 2 | 0.230 |
Why?
|
| Fractures, Bone | 1 | 2024 | 21 | 0.230 |
Why?
|
| Piperazines | 1 | 2024 | 82 | 0.230 |
Why?
|
| Oxazines | 1 | 2024 | 81 | 0.230 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 85 | 0.230 |
Why?
|
| Sleep | 2 | 2021 | 36 | 0.220 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.220 |
Why?
|
| Intra-Abdominal Fat | 2 | 2020 | 15 | 0.220 |
Why?
|
| Aged | 4 | 2021 | 1740 | 0.220 |
Why?
|
| Hydrocortisone | 2 | 2014 | 10 | 0.220 |
Why?
|
| Focus Groups | 1 | 2024 | 196 | 0.220 |
Why?
|
| Ergometry | 2 | 2013 | 2 | 0.210 |
Why?
|
| Risk Factors | 3 | 2022 | 1475 | 0.210 |
Why?
|
| C-Peptide | 1 | 2022 | 13 | 0.210 |
Why?
|
| Proteomics | 1 | 2022 | 15 | 0.210 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cytokines | 2 | 2014 | 107 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2023 | 45 | 0.200 |
Why?
|
| MicroRNAs | 1 | 2022 | 34 | 0.200 |
Why?
|
| Waist Circumference | 3 | 2022 | 60 | 0.200 |
Why?
|
| Jet Lag Syndrome | 2 | 2020 | 2 | 0.200 |
Why?
|
| Africa South of the Sahara | 1 | 2023 | 353 | 0.190 |
Why?
|
| Biomarkers | 2 | 2013 | 327 | 0.190 |
Why?
|
| Cell Respiration | 1 | 2021 | 1 | 0.190 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 85 | 0.180 |
Why?
|
| Food Supply | 1 | 2021 | 29 | 0.180 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 1 | 0.180 |
Why?
|
| Air Travel | 1 | 2020 | 4 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2020 | 7 | 0.180 |
Why?
|
| Light | 1 | 2020 | 12 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2020 | 11 | 0.180 |
Why?
|
| Hyperinsulinism | 1 | 2020 | 4 | 0.180 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 7 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 41 | 0.180 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 4 | 0.170 |
Why?
|
| Hydrogen Peroxide | 1 | 2020 | 11 | 0.170 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 370 | 0.170 |
Why?
|
| African Americans | 1 | 2020 | 47 | 0.170 |
Why?
|
| Epidemics | 1 | 2020 | 65 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 237 | 0.160 |
Why?
|
| Quality of Life | 1 | 2021 | 177 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 411 | 0.160 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 9 | 0.160 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2016 | 5 | 0.150 |
Why?
|
| Soccer | 1 | 2018 | 10 | 0.150 |
Why?
|
| Sports Medicine | 1 | 2018 | 19 | 0.150 |
Why?
|
| High-Intensity Interval Training | 1 | 2017 | 1 | 0.140 |
Why?
|
| Fructose | 1 | 2017 | 1 | 0.140 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2017 | 2 | 0.140 |
Why?
|
| Prevalence | 1 | 2021 | 1192 | 0.140 |
Why?
|
| Dietary Sugars | 1 | 2017 | 7 | 0.140 |
Why?
|
| Health Promotion | 1 | 2018 | 109 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 46 | 0.140 |
Why?
|
| Rest | 1 | 2016 | 2 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 2 | 0.140 |
Why?
|
| Muscle Contraction | 1 | 2016 | 5 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 7 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2016 | 32 | 0.140 |
Why?
|
| Smoking | 1 | 2016 | 100 | 0.130 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Sirtuin 1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| MEF2 Transcription Factors | 1 | 2015 | 1 | 0.130 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2015 | 2 | 0.130 |
Why?
|
| PPAR gamma | 1 | 2015 | 3 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 9 | 0.120 |
Why?
|
| Adiponectin | 1 | 2014 | 15 | 0.120 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 29 | 0.120 |
Why?
|
| Cholecalciferol | 2 | 2024 | 8 | 0.120 |
Why?
|
| New South Wales | 1 | 2013 | 4 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 14 | 0.110 |
Why?
|
| Vitamin D | 2 | 2024 | 41 | 0.110 |
Why?
|
| Dietary Supplements | 2 | 2024 | 40 | 0.110 |
Why?
|
| Double-Blind Method | 2 | 2024 | 272 | 0.110 |
Why?
|
| Child | 3 | 2024 | 2242 | 0.100 |
Why?
|
| Homeostasis | 1 | 2012 | 9 | 0.100 |
Why?
|
| Population | 1 | 2010 | 5 | 0.090 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2020 | 3 | 0.090 |
Why?
|
| Time Factors | 1 | 2010 | 507 | 0.080 |
Why?
|
| Motivation | 2 | 2020 | 59 | 0.080 |
Why?
|
| Diet | 2 | 2021 | 109 | 0.080 |
Why?
|
| Oxidation-Reduction | 2 | 2019 | 24 | 0.070 |
Why?
|
| Calcifediol | 1 | 2024 | 6 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2024 | 11 | 0.060 |
Why?
|
| Spirometry | 1 | 2024 | 12 | 0.060 |
Why?
|
| Vitamins | 1 | 2024 | 23 | 0.060 |
Why?
|
| Bone Density | 1 | 2024 | 107 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 81 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 17 | 0.050 |
Why?
|
| Scotland | 1 | 2021 | 5 | 0.050 |
Why?
|
| Switzerland | 1 | 2021 | 2 | 0.050 |
Why?
|
| Eating | 1 | 2021 | 16 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 198 | 0.050 |
Why?
|
| Athletes | 1 | 2020 | 20 | 0.050 |
Why?
|
| Return to Sport | 1 | 2020 | 3 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 442 | 0.040 |
Why?
|
| Buttocks | 1 | 2020 | 1 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 1 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 10 | 0.040 |
Why?
|
| Oxygen | 1 | 2020 | 25 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 20 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2020 | 19 | 0.040 |
Why?
|
| Athletic Injuries | 1 | 2020 | 42 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2019 | 13 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 376 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 967 | 0.040 |
Why?
|
| Aryldialkylphosphatase | 1 | 2018 | 3 | 0.040 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2018 | 4 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2018 | 25 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 1160 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 34 | 0.040 |
Why?
|
| Qatar | 1 | 2017 | 1 | 0.040 |
Why?
|
| United Arab Emirates | 1 | 2017 | 1 | 0.040 |
Why?
|
| Travel | 1 | 2017 | 21 | 0.040 |
Why?
|
| Perception | 1 | 2017 | 42 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.040 |
Why?
|
| Reperfusion | 1 | 2017 | 1 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2017 | 6 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 23 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 45 | 0.040 |
Why?
|
| Myocardium | 1 | 2017 | 35 | 0.030 |
Why?
|
| Triglycerides | 1 | 2017 | 47 | 0.030 |
Why?
|
| Heart | 1 | 2017 | 27 | 0.030 |
Why?
|
| Carnitine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Coenzyme A | 1 | 2016 | 1 | 0.030 |
Why?
|
| Malates | 1 | 2016 | 1 | 0.030 |
Why?
|
| Palmitoylcarnitine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2016 | 1 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2016 | 2 | 0.030 |
Why?
|
| Electrodes | 1 | 2016 | 7 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2016 | 2 | 0.030 |
Why?
|
| Animals | 1 | 2017 | 1081 | 0.030 |
Why?
|